Newsroom

News March 8, 2023

World Renowned Childhood Blood Cancer Expert Named as The Leukemia & Lymphoma Society's New President and CEO

The Leukemia & Lymphoma Society (LLS), the global leader and innovator in creating a world without blood cancer, is proud to announce E. Anders Kolb, …

News March 8, 2023

FDA Approves New Formulation of Important Childhood Leukemia Drug

The U.S. Food and Drug Administration yesterday approved nelarabine injection, a critical treatment for T-cell acute lymphoblastic leukemia (T-ALL), a…

Patient Education Videos March 3, 2023

Nutrition

These videos share tips, recipes, information about nutrition and wellness, and more.

Patient Education Webcasts February 16, 2023

Treatment Advancements for Acute Lymphoblastic Leukemia (ALL) in Children and Adults

Research February 9, 2023

Faron Announces Results of Placing, Including Additional Investment by The Leukemia & Lymphoma Society Therapy Acceleration Program®

TURKU, FINLAND / BOSTON, MA - January 27 2023 - Faron Pharmaceuticals Ltd (First North: FARON, AIM: FARN), a clinical stage biopharmaceutical company …

Patient Education Webcasts February 2, 2023

CAR T-Cell Therapy and Blood Cancers

News February 1, 2023

Sharing Decades of a Dedicated Vision to End Cancer

Sharing Decades of a Dedicated Vision to End Cancer

January 30, 2023

LLS Community Corner Log In Instructions

News January 27, 2023

FDA Approves New Type of BTK Inhibitor to Treat Mantle Cell Lymphoma

The U.S. Food and Drug Administration today approved pirtobrutinib (Jaypirca™), the first non-covalent, reversable BTK inhibitor for the treatment of …

January 17, 2023

Apoyo Económico

January 17, 2023

Alivio financiero

Research January 17, 2023

Encouraging Additional Data for Bexmarilimab for the Treatment of Hematological Malignancies

January 16, 2023 - TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company …